Sintx Technologies, Inc. (SINT), Monday announced it has secured the U.S. Food and Drug Administration 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System, paving its way into the billion-dollar reconstructive foot and ankle surgery market.
The system, which integrates SINTX's proprietary silicon nitride biomaterial with surgeon-informed implant designs and a single-use instrument kit, is expected to be commercially available in the U.S. market in the first quarter of 2026.
CEO Eric Olson, Chairman commented, "By entering the high-value, procedure-driven market with a differentiated biomaterial and surgeon-validated designs, we expect to generate meaningful clinical impact and build shareholder value as we execute our commercial strategy."
In the pre-market hours, SINT is trading at $4.08, up 3.53 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.